/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome
Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos · Oct 21, 2026

CD20xCD3 bispecifics in NHL: step-up dosing, CRS is early and manageable; outpatient protocols and community infrastructure are key.

Avoid bendamustine before CAR T in rituximab-refractory FL

Manali says that in rituximab-refractory follicular lymphoma she avoids chemotherapy such as bendamustine because a later CD19 CAR T option may be compromised by prior bendamustine. She would rather use Epco-R2 or MosinLen, preserving the CAR T path for patients who need it. She frames this as a key sequencing decision.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Inflammatory markers are not CRS-specific in practice

Alex says baseline CRP, ferritin and IL-6 help interpret later changes when a patient develops fever, but they are not specific to CRS and should not guide treatment. IL-6 rises after tocilizumab because the receptor is blocked, making subsequent values hard to interpret in practice.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Community bispecific launch needs ER and ICU education

Spencer, at Lynn Cancer Institute, says his committee had to update multiple EMRs, teach ER doctors, ICU staff, residents and hospitalists about CRS, ensure tocilizumab is available after hours, and secure STAT CMP testing. He describes the coordination across stakeholders as very difficult and the main operational barrier to launching bispecifics.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Third-line DLBCL still favors CAR T for cure

Manali says third-line DLBCL still favors CD19 CAR T when patients are eligible and CAR-naive, because about 40% have a flat five-year curve suggesting cure. Bispecifics show durable complete responses at three years, but follow-up is shorter. She sequences CAR T first, then a CD20 bispecific.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Dexamethasone may beat other steroids for bispecific CRS

Jennifer cites a retrospective glofitamab analysis where dexamethasone was associated with lower CRS or less need for additional support than other steroids. Its longer half-life and greater potency made dexamethasone the preferred steroid at Dana-Farber, although she notes the evidence is only retrospective for this drug class.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Home dexamethasone can avoid admission for grade 1 CRS

Alex and Jennifer describe a 'pill in pocket' approach: patients keep dexamethasone at home. If they call with fever but stable vital signs, they take one dose, monitor temperature every one to two hours, and call back for recurrent fever. Many avoid admission, though repeat fever triggers evaluation.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Vaccinate before or a year after bispecific

Alex says one-and-done vaccines such as RSV, shingles and pneumonia are best given before a bispecific or at least a year after, when immune response is likely better. Flu and COVID vaccines are still recommended, but she spaces them six to eight weeks before PET to avoid vaccine-related adenopathy.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Step-up at tertiary center then transfer may work

Spencer describes a phased plan where patients receive first bispecific doses at a tertiary center and then transfer back to the community. Jennifer and Alex note CRS is mostly front-loaded, with delayed events rare beyond early doses. This model reduces community safety burden, but the community still must handle later fevers.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Preemptive admission should target comorbidity and support

Alex admits some patients preemptively even when outpatient dosing is possible: those living alone with limited support, patients with heart failure or chronic kidney disease, and those with high tumor burden, LDH above 1,000, or malignant effusions. The aim is faster recognition and treatment of CRS.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

No prophylactic tocilizumab for lymphoma bispecifics

Manali says there is no data for prophylactic tocilizumab with lymphoma CD20 bispecifics, unlike myeloma, so she does not use it. Patients instead receive PJP and HSV prophylaxis and have IgG checked, with IVIG for IgG below 400 or recurrent infections. That prophylaxis package differs from CAR T.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Second-line follicular lymphoma choice hinges on infection risk

Manali reports Epco-R2's phase 3 follicular lymphoma trial showed a hazard ratio of 0.2 for PFS, but grade 3 or higher infections hit 33% and neutropenia 69%. MosinLen had less infection and is a time-limited doublet. If approved, the choice may trade triplet efficacy for better tolerability.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Confirm CD20 before every bispecific, even post-CAR T

Manali emphasizes that CD20 expression must be reconfirmed by flow cytometry or IHC before any CD20 bispecific, because the drug cannot work without its target. In her case, a patient retained CD20 after CAR T and then received glofitamab, showing prior CAR T does not rule out bispecific therapy.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Glofitamab's obinutuzumab pre-dose is not optional

Manali explains glofitamab binds the same CD20 epitope as obinutuzumab and had high CRS, so the label requires obinutuzumab seven days before the first step-up. Mosunetuzumab shares rituximab's epitope, meaning a mosunetuzumab-rituximab combination would compete for the same binding domain. That mechanistic detail shapes regimen design.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

CRS timing is dose- and agent-specific

Jennifer shows CRS timing differs by drug: glofitamab peaks at the first 2.5 mg step-up, epcoritamab at its first full dose, and mosunetuzumab at the third dose. Follicular lymphoma's extra epcoritamab step-up lowered high-grade CRS. Outpatient monitoring must match the exact agent and dose in practice.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

At-home flu and COVID tests clarify CRS vs infection

Alex has bispecific patients keep flu and COVID tests at home because fever workup must still rule out infection. In one case, a patient had recurrent CRS fevers and later tested positive for flu B, with cough and congestion distinguishing the infection from her earlier fever-only CRS.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Debulking chemo lowers CRS but creates febrile neutropenia

Jennifer describes a glofitamab plus Pola-R-CHP trial where two chemotherapy cycles before the bispecific produced almost no CRS, likely from debulking. But patients then received the bispecific at chemotherapy nadir, making febrile neutropenia a real challenge if phase 3 succeeds and the regimen is adopted.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Triplet neutropenia can be managed by holding lenalidomide

Manali says Epco-R2 caused grade 3 or higher neutropenia in 69% of patients, so co-management with community partners often means dose-reducing or holding lenalidomide to keep epcoritamab going. This practical lever matters as the triplet enters second-line follicular lymphoma practice. It may prevent unnecessary epcoritamab discontinuation.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago

Community access fails on travel, not just toxicity

Tina says her West Virginia site is ninety minutes from academic care, and older follicular lymphoma patients often decline bispecifics because of travel and parking. Spencer sees the same barrier at his Boca Raton site. Repeated bispecific visits are harder than a one-time CAR T trip.

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome thumbnail

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome

Research To Practice | Oncology Videos·a month ago